- Insulin
- Biguanides
- Sulfonyl Ureas
- Thiazolidinediones
- Di Peptidyl Peptidase (DPP)-IV Inhibitors
- ?-glucosidase Inhibitos
- GLP-1 Agonists
- Others
Middle East And Africa Anti Diabetic Biosimilars Market size was valued at USD X in 2023 and is poised to grow at a CAGR of X% from 2024-2030.Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.
Middle East And Africa Anti Diabetic Biosimilars Market Dynamics
Drivers:
- Increase in the prevalence of diabetes
- Low cost of biosimilars compared with reference biologic molecules
- Expansion of business by the market players
Restraints:
- High cost and longer duration of R&D activities
- Stringent regulatory policies
- Complexity in development of biosimilars
Key Features of the Reports
- The middle east and africa anti diabetic biosimilars market report provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Middle East And Africa Anti Diabetic Biosimilars Market Segmentation
By Durg Class
By Disease Type
- Type-I Diabetes
- Type-II Diabetes
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
Frequently Asked Questions
middle east and africa anti diabetic biosimilars market size was valued at USD X in 2023 and is poised to grow at a CAGR of X% from 2024-2030.
The middle east and africa anti diabetic biosimilars market report covers: Saudi Arabia, United Arab Emirates, South Africa
The middle east and africa anti diabetic biosimilars market key players are Merck Sharp & Dohme Corporation Boehringer Ingelheim GmbH Eli Lilly & Co.Sanofi-aventis U.S. LLC Samsung Bioepis (Samsung BioLogics)Mylan N.V. Wockhardt
| 1.Executive Summary |
| 2. Middle East And Africa Anti Diabetic Biosimilars Market Introduction |
| 2.1. Middle East And Africa Anti Diabetic Biosimilars Market - Taxonomy |
| 2.2. Middle East And Africa Anti Diabetic Biosimilars Market - Definitions |
| 2.2.1.Durg Class |
| 2.2.2.Disease Type |
| 2.2.3.Distribution Channel |
| 2.2.4.Country |
| 3. Middle East And Africa Anti Diabetic Biosimilars Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Middle East And Africa Anti Diabetic Biosimilars Market Analysis, 2019 -2023 and Forecast 2024 -2030 |
| 4.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Middle East And Africa Anti Diabetic Biosimilars Market By Durg Class, 2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 5.1. Insulin |
| 5.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Biguanides |
| 5.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sulfonyl Ureas |
| 5.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Thiazolidinediones |
| 5.4.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 5.5.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. ?-glucosidase Inhibitos |
| 5.6.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. GLP-1 Agonists |
| 5.7.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Others |
| 5.8.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6. Middle East And Africa Anti Diabetic Biosimilars Market By Disease Type, 2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 6.1. Type-I Diabetes |
| 6.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Type-II Diabetes |
| 6.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Middle East And Africa Anti Diabetic Biosimilars Market By Distribution Channel, 2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Middle East And Africa Anti Diabetic Biosimilars Market By Country, 2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 8.1. South Africa |
| 8.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Middle East and Africa (MEA) |
| 8.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. GCC Countries |
| 8.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Rest of MEA |
| 8.4.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9.South Africa Middle East And Africa Anti Diabetic Biosimilars Market ,2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 9.1. Durg Class Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Insulin |
| 9.1.2.Biguanides |
| 9.1.3.Sulfonyl Ureas |
| 9.1.4.Thiazolidinediones |
| 9.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 9.1.6.?-glucosidase Inhibitos |
| 9.1.7.GLP-1 Agonists |
| 9.1.8.Others |
| 9.2. Disease Type Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Type-I Diabetes |
| 9.2.2.Type-II Diabetes |
| 9.3. Distribution Channel Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 10.Middle East and Africa (MEA) Middle East And Africa Anti Diabetic Biosimilars Market ,2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 10.1. Durg Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Insulin |
| 10.1.2.Biguanides |
| 10.1.3.Sulfonyl Ureas |
| 10.1.4.Thiazolidinediones |
| 10.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 10.1.6.?-glucosidase Inhibitos |
| 10.1.7.GLP-1 Agonists |
| 10.1.8.Others |
| 10.2. Disease Type Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Type-I Diabetes |
| 10.2.2.Type-II Diabetes |
| 10.3. Distribution Channel Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 11.GCC Countries Middle East And Africa Anti Diabetic Biosimilars Market ,2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 11.1. Durg Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Insulin |
| 11.1.2.Biguanides |
| 11.1.3.Sulfonyl Ureas |
| 11.1.4.Thiazolidinediones |
| 11.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 11.1.6.?-glucosidase Inhibitos |
| 11.1.7.GLP-1 Agonists |
| 11.1.8.Others |
| 11.2. Disease Type Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Type-I Diabetes |
| 11.2.2.Type-II Diabetes |
| 11.3. Distribution Channel Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 12.Rest of MEA Middle East And Africa Anti Diabetic Biosimilars Market ,2019 -2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 12.1. Durg Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Insulin |
| 12.1.2.Biguanides |
| 12.1.3.Sulfonyl Ureas |
| 12.1.4.Thiazolidinediones |
| 12.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 12.1.6.?-glucosidase Inhibitos |
| 12.1.7.GLP-1 Agonists |
| 12.1.8.Others |
| 12.2. Disease Type Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Type-I Diabetes |
| 12.2.2.Type-II Diabetes |
| 12.3. Distribution Channel Analysis 2019 -2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Merck Sharp & Dohme Corporation |
| 13.2.2.Boehringer Ingelheim GmbH |
| 13.2.3.Eli Lilly & Co. |
| 13.2.4.Sanofi-aventis U.S. LLC |
| 13.2.5.Samsung Bioepis (Samsung BioLogics) |
| 13.2.6.Mylan N.V. |
| 13.2.7.Wockhardt |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Merck Sharp & Dohme Corporation
- Boehringer Ingelheim GmbH
- Eli Lilly & Co.
- Sanofi-aventis U.S. LLC
- Samsung Bioepis (Samsung BioLogics)
- Mylan N.V.
- Wockhardt